Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsRichard Chen, PA
Clinical InstructorAbout
Research
Publications
2025
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy.
Garralda E, Abbott C, Calahorro A, Mirallas O, Pugh J, Moreno-Cárdenas A, Keough K, Galvao V, Alonso G, Olano A, Vieito Villar M, Oberoi A, Lostes Bardaji J, Hernando-Calvo A, Braña I, Pretelli G, Ortega B, Arenillas C, Czerniak N, Navarro F, Li B, Pyke R, Ravi N, Zatse C, Grussu F, Sanz M, Viaplana C, Raskina K, Jimenez J, Fasani R, Casbas-Hernandez P, Oflazoglu E, Hodgson D, Reis-Filho J, Felip E, Élez E, Muñoz E, Dienstmann R, Tabernero J, Lopez-Perez R, Nuciforo P, Chen R, Boyle S, Toledo R. Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy. Clinical Cancer Research 2025, of1-of17. PMID: 41400436, DOI: 10.1158/1078-0432.ccr-25-2312.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsCheckpoint inhibitorsCtDNA dynamicsProgression-FreeOverall survivalCancer treated with immunotherapyTumor-specific mutationsCohort of patientsProspective validation cohortImmune cell engagementBiomarker potentialCtDNA clearanceImmunotherapy modalitiesRadiological responseProlonged survivalCtDNA detectionTreatment initiationTrue progressionRetrospective cohortValidation cohortCell engagementImmunotherapyBispecific antibodiesCancer typesPatientsUltrasensitive ctDNA monitoring to reveal early predictors of immunotherapy success in advanced cancer.
Nishizaki D, Law A, Abbott C, Chen Y, Li B, Lee S, Daniels G, Yeung K, Boyle S, Chen R, Kato S. Ultrasensitive ctDNA monitoring to reveal early predictors of immunotherapy success in advanced cancer. Journal Of Clinical Oncology 2025, 43: 2561-2561. DOI: 10.1200/jco.2025.43.16_suppl.2561.Peer-Reviewed Original ResearchCirculating tumor DNAProgression-free survivalImmune checkpoint inhibitionCtDNA monitoringTumor DNAPredictors of progression-free survivalCtDNA-based liquid biopsiesMinimal residual disease assessmentCirculating tumor DNA levelsImmune checkpoint inhibition therapyMolecular complete responseYear PFS ratesPlasma samplesProgression-free statusResidual disease assessmentLiquid biopsy approachLongitudinal plasma samplesPrediction of therapeutic outcomeEarly molecular responseEvaluation of immunotherapy responseEarly prediction of therapeutic outcomesBaseline to first follow-upCtDNA kineticsFirst follow-upImmunotherapy successUltrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC).
Cabel L, Lamy C, Keough K, Abbott C, Pouget N, Pierga J, Sablin M, Flavius J, Bronzini T, Laas E, Darrigues L, Feron J, Fourchotte V, Bonneau C, Vincent-Salomon A, Boyle S, Chen R, Le Tourneau C, Bidard F. Ultrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC). Journal Of Clinical Oncology 2025, 43: 552-552. DOI: 10.1200/jco.2025.43.16_suppl.552.Peer-Reviewed Original ResearchTriple-negative breast cancerPathological complete responsePost-NACCtDNA detectionFollow-upPlasma ctDNADistant metastasisDistant relapse-free intervalPathological complete response statusPatients treated with NACTriple-negative breast cancer patientsEarly-stage TNBC patientsPost-surgical follow-upCtDNA-negative patientsCtDNA-positive patientsPost-neoadjuvant chemotherapyResidual disease levelsStratify survival outcomesImmune checkpoint inhibitorsNon-relapsing patientsRelapse-free intervalAdjuvant treatment decisionsMedian Follow-UpTumor-specific variantsMultivariate Cox modelClinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Galsky M, Autio K, Cabanski C, Wentzel K, Graff J, Friedlander T, Howes T, Shotts K, Densmore J, Spasic M, Da Silva D, Chen R, Lata J, Skolnik J, Keler T, Yellin M, LaVallee T, Fairchild J, Boffo S, O’Donnell-Tormey J, Dugan U, Bhardwaj N, Subudhi S, Fong L. Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research 2025, 31: 1463-1475. PMID: 39964352, PMCID: PMC11995007, DOI: 10.1158/1078-0432.ccr-24-3693.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerProstate cancerPoly-ICLCAdverse eventsGrade 3 to 4 treatment-related adverse eventsAssociated with clinical benefitAssociated with disease controlResponse rateDisease control rateProgression-free survivalImmune checkpoint therapyComposite response rateCycles 1 to 3Disease controlCDX-301Combination immunotherapyCombined radiotherapyCheckpoint therapyImmunotherapy efficacyOverall survivalOpen-labelPrimary endpointSecondary endpointsCohort BWhole genome sequencing-powered ctDNA sequencing for breast cancer detection
Garcia-Murillas I, Abbott C, Cutts R, Boyle S, Pugh J, Keough K, Li B, Pyke R, Navarro F, Chen R, Dunne K, Bunce C, Johnston S, Ring A, Russell S, Evans A, Skene A, Smith I, Turner N. Whole genome sequencing-powered ctDNA sequencing for breast cancer detection. Annals Of Oncology 2025, 36: 673-681. PMID: 39914664, DOI: 10.1016/j.annonc.2025.01.021.Peer-Reviewed Original ResearchConceptsMolecular residual diseaseClinical relapseHigh riskCtDNA detectionDetection of molecular residual diseaseFollow-upAssociated with relapse-free survivalHigh risk of relapseMedian levelRelapse-free survivalBreast cancer relapseCirculating tumor DNARisk of relapseAssociated with higher riskBreast cancer patientsMedian lead timeLevels of ctDNADetection of ctDNANeoadjuvant therapyResidual diseaseNeoadjuvant chemotherapyOverall survivalPlasma DNATumor DNACancer relapseIdentifying the optimal post-surgical timing of molecular residual disease (MRD) detection in colorectal cancer (CRC) using an ultra-sensitive assay: Interim results from the VICTORI study.
Solar Vasconcelos J, Titmuss E, Navarro F, Abbott C, Chia B, Topham J, Ladua G, Krishnan T, Hegebarth D, Lim H, Gill K, Gill S, Brown C, Ghuman A, Meneghetti A, Renouf D, Schaeffer D, Chen R, Boyle S, Loree J. Identifying the optimal post-surgical timing of molecular residual disease (MRD) detection in colorectal cancer (CRC) using an ultra-sensitive assay: Interim results from the VICTORI study. Journal Of Clinical Oncology 2025, 43: 275-275. DOI: 10.1200/jco.2025.43.4_suppl.275.Peer-Reviewed Original ResearchMolecular residual diseaseColorectal cancerCtDNA detectionDetection of molecular residual diseaseWeek 8Week 4Resectable colorectal cancerYear of surgeryTime of surgerySingle nucleotide variantsYear Follow-UpPost-surgical timesNeoadjuvant therapyResidual diseaseCurative intentMRD assaysResidual cancerClinical relapseDisease recurrenceCtDNA concentrationRecurrent cancerClinical outcomesCfDNA concentrationFollow-upRecurrenceUltrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
Black J, Bartha G, Abbott C, Boyle S, Karasaki T, Li B, Chen R, Harris J, Veeriah S, Colopi M, Bakir M, Liu W, Lyle J, Navarro F, Northcott J, Pyke R, Hill M, Thol K, Huebner A, Bailey C, Colliver E, Martínez-Ruiz C, Grigoriadis K, Pawlik P, Moore D, Marinelli D, Shutkever O, Murphy C, Sivakumar M, Shaw J, Hackshaw A, McGranahan N, Jamal-Hanjani M, Frankell A, Chen R, Swanton C. Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma. Nature Medicine 2025, 31: 70-76. PMID: 39806071, PMCID: PMC11750713, DOI: 10.1038/s41591-024-03216-y.Peer-Reviewed Original ResearchConceptsCirculating tumor DNAEarly-stage lung adenocarcinomaLung adenocarcinomaPathological TNMCtDNA detectionDisease stratificationEarly-stage lung cancerStage I diseaseEarly-stage tumorsCtDNA levelsI diseaseOverall survivalTumor DNAClinical outcomesPre-operativelyProspective studyLung cancerClinical utilityClinical riskPatientsClinical applicationAdenocarcinomaTRACERx study
2024
P21-8 Ultra-sensitive tumor-informed ctDNA assay predicts survival in advanced melanoma patients treated with ICI treatment
Pan H, Keller L, Heidrich I, Kott J, Abbott C, Boyle S, Pugh J, Chen R, Geidel G, Ronald S, Schneider S, Gebhardt C, Pantel K. P21-8 Ultra-sensitive tumor-informed ctDNA assay predicts survival in advanced melanoma patients treated with ICI treatment. Annals Of Oncology 2024, 35: s1373. DOI: 10.1016/j.annonc.2024.07.398.Peer-Reviewed Original Research223P Tumor whole genome sequencing-based ultrasensitive ctDNA analysis as an early biomarker for clinical outcome in immune checkpoint inhibitor (ICI) phase I clinical trials (Ph1) and a tool for beyond progressive disease by iRECIST
Toledo R, García A, Moreno A, Mirallas O, Galvao V, Casal G, Vieito M, Braña I, Oberoi A, Bardaji M, Keough K, Navarro F, Jimenez J, Olano A, Nuciforo P, Abbott C, Pugh J, Chen R, Boyle S, Garralda E. 223P Tumor whole genome sequencing-based ultrasensitive ctDNA analysis as an early biomarker for clinical outcome in immune checkpoint inhibitor (ICI) phase I clinical trials (Ph1) and a tool for beyond progressive disease by iRECIST. Annals Of Oncology 2024, 35: s304-s305. DOI: 10.1016/j.annonc.2024.08.2227.Peer-Reviewed Original ResearchLBA9 Clinical insights from ultra-sensitive tumour-informed ctDNA tracking across the TRACERx cohort
Black J, Karasaki T, Abbott C, Boyle S, Li B, Al Bakir M, Liu W, Veeriah S, Jamal-Hanjani M, McGranahan N, Frankell A, Chen R, Swanton C. LBA9 Clinical insights from ultra-sensitive tumour-informed ctDNA tracking across the TRACERx cohort. Annals Of Oncology 2024, 35: s1203. DOI: 10.1016/j.annonc.2024.08.2246.Peer-Reviewed Original Research